ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0899

Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis

Ting-Shuan Wu1 and Yi-Ming Chen2, 1Chung Shan Medical University, Taichung, Taiwan (Republic of China), 2Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China)

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Biomarkers, Disease-Modifying Antirheumatic Drugs (Dmards), proteomics, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) is a common and complex inflammatory polyarthritis. Janus kinase inhibitors (JAKi) have shown superior efficacy compared to traditional treatments, but predictors for therapeutic response are yet to discover. Our aim is to utilize the proteomics OLINK analysis method to identify biomarkers associated with the effectiveness of JAKi in patients with RA, thereby providing treatment strategy for precision medicine.

Methods: This study enrolled RA patients from Taichung Veterans General Hospital, Taiwan. Therapeutic effectiveness was classified according to EULAR response criteria. Plasma proteins were collected before JAKi treatment, and a proteomic analysis using the OLINK inflammation platform examined differences in plasma protein levels between groups.

Results: The overall good response rate to JAKi was 54.76% (58.33% in patients treated with baricitinib, 35.71% with tofacitinib, and 68.75% with upadacitinib). Elevated pre-treatment plasma levels of interleukin (IL)-12B, IL-17A, and interferon (IFN)-γ were associated with poor responses to JAK inhibitors. High IFN-γ and IL-12B levels were linked to poor responses to baricitinib, while high IL-17A levels were associated with poor responses to tofacitinib. No protein markers were found related to poor responses to upadacitinib. Pathway analysis using Gene Set Enrichment Analysis (GSEA) provided insights into the signaling pathways regulated by JAK inhibitors after treatment.

Conclusion: IFN-γ, IL-12B, and IL-17A may serve as biomarkers for JAKi treatment responsiveness in RA patients, aiding rheumatologists in making more accurate drug choices and improving patient outcomes.

Supporting image 1

Differentially expressed inflammation-related biomarkers between the RA patients

Supporting image 2

Candidate protein expressions between response and non-response


Disclosures: T. Wu: None; Y. Chen: None.

To cite this abstract in AMA style:

Wu T, Chen Y. Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/proteomic-insights-into-jak-inhibitor-therapeutic-response-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteomic-insights-into-jak-inhibitor-therapeutic-response-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology